These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9733365)

  • 21. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peripheral and central imidazoline receptor-mediated natriuresis in the rat.
    Smyth DD; Penner SB
    Ann N Y Acad Sci; 1999 Jun; 881():344-57. PubMed ID: 10415934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of moxonidine on cardiac autonomic modulation.
    Kaya D; Barutcu I; Esen AM; Celik A; Onrat E
    Pacing Clin Electrophysiol; 2010 Aug; 33(8):929-33. PubMed ID: 20230461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atrial natriuretic peptide is involved in renal actions of moxonidine.
    Mukaddam-Daher S; Gutkowska J
    Hypertension; 2000 Jun; 35(6):1215-20. PubMed ID: 10856266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal denervation altered the hemodynamic and renal effects following intracerebroventricular administration of the I1-imidazoline receptor agonist, rilmenidine, in pentobarbital anaesthetized rats.
    Penner SB; Smyth DD
    Neurochem Int; 1997 Jan; 30(1):55-62. PubMed ID: 9116588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal imidazoline preferring sites and solute excretion in the rat.
    Allan DR; Penner SB; Smyth DD
    Br J Pharmacol; 1993 Apr; 108(4):870-5. PubMed ID: 8097955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptors involved in moxonidine-stimulated atrial natriuretic peptide release from isolated normotensive rat hearts.
    Mukaddam-Daher S; Menaouar A; Gutkowska J
    Eur J Pharmacol; 2006 Jul; 541(1-2):73-9. PubMed ID: 16774751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine.
    Urban R; Szabo B; Starke K
    Eur J Pharmacol; 1995 Aug; 282(1-3):19-28. PubMed ID: 7498275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apparent absence of direct renal effect of imidazoline receptor agonists.
    Smyth DD; Pirnat D; Forzley B; Penner SB
    Ann N Y Acad Sci; 2003 Dec; 1009():288-95. PubMed ID: 15028602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of moxonidine and clonidine on potassium excretion in Sprague-Dawley rats.
    Hohage H; Mehrens T; Matzkies F; Steinmetz M; Greven J
    Pharmacol Res; 1999 May; 39(5):357-61. PubMed ID: 10328993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides.
    Mukaddam-Daher S; Gutkowska J
    Braz J Med Biol Res; 2004 Aug; 37(8):1239-45. PubMed ID: 15273826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
    Ernsberger P; Damon TH; Graff LM; Schäfer SG; Christen MO
    J Pharmacol Exp Ther; 1993 Jan; 264(1):172-82. PubMed ID: 8380858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal and blood pressure effects of moxonidine and clonidine in spontaneously hypertensive rats.
    Hohage H; Hess K; Jahl C; Greven J; Schlatter E
    Clin Nephrol; 1997 Dec; 48(6):346-52. PubMed ID: 9438092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of putative imidazoline (I1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential.
    Evans RG
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):845-54. PubMed ID: 8911724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
    Paulsen L; Holm C; Bech JN; Starklint J; Pedersen EB
    Nephrol Dial Transplant; 2008 May; 23(5):1556-61. PubMed ID: 18065809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of moxonidine in the treatment of hypertension.
    Prichard BN; Graham BR
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.